Kalabie ELN Highly Complementary to Agilent OpenLAB
SANTA CLARA, Calif.--(BUSINESS WIRE)--June 18, 2007--Agilent
Technologies Inc. (NYSE:A) today announced it has acquired the Klee
Group's Kalabie Electronic Laboratory Notebook (ELN). The focus for
this product, which is Agilent's first electronic notebook, will be on
the pharmaceutical market and some chemical applications. Financial
details of the acquisition were not disclosed.
Kalabie ELN is a highly configurable software solution for the R&D
sector, used by leading pharmaceutical and dermo-cosmetic companies
since 2004 to boost productivity and enhance collaboration of
chemistry and biology scientists. A digital laboratory notebook,
Kalabie ELN provides a foundation for knowledge and process management
as well as intellectual property protection within laboratories.
Kalabie ELN centralizes and secures all data from experimental work
with a high level of traceability. Offering a rich package of features
plus flexibility, Kalabie ELN can be deployed as a standard packaged
solution or it can be configured to meet customers' specific needs.
Agilent's current portfolio of laboratory software includes
OpenLAB -- the operating system for the laboratory. Agilent plans to
integrate the Kalabie ELN product into OpenLAB in the next six months
to provide customers with the ability to manage computing resources in
the laboratory with a complete solution.
"With the addition of Kalabie, Agilent can provide customers with
a complete software solution and a single-vendor approach to their
laboratory management needs," said Bruce von Herrmann, vice president
and general manager for Agilent's Software and Informatics Division.
"ELNs simplify knowledge and data integration. The combined
capabilities of Kalabie ELN, OpenLAB and GeneSpring provide unique
capabilities that enhance productivity."
"Integrating into Agilent's software and informatics portfolio is
exciting for the Kalabie ELN team," said Alain Meller, Kalabie
director at the Klee Group. "This will immediately provide our
customers the benefits of Agilent's global reach and support
capabilities, allowing for rapid deployment of ELN solutions across
organizations and geographies. Moreover, with the combined
capabilities that Agilent OpenLAB offers, we will speed up our ability
to market and deliver high-value, global, integrated lab informatics
solutions where the ELN is a key component."
Prior to its acquisition by Agilent, Kalabie was a division of
Klee Group, an information systems consulting firm founded in 1987. It
is a private company based in France, Spain and Italy. All members of
the Kalabie team have joined Agilent and will continue to be based in
Paris and Montpellier, France. More information about Kalabie is
available at www.kalabie.com.
Agilent in Life Sciences and Chemical Analysis
Agilent's Life Sciences and Chemical Analysis (LSCA) business is a
world-leading provider of instruments, supplies, software and services
to the life science and chemical analysis markets. It is a leading
provider of microarray, microfluidic, liquid chromatography, gas
chromatography, mass spectrometry and informatics-based solutions to
pharmaceutical, biotech, academic, government and chemical
organizations.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A) is the world's premier
measurement company and a technology leader in communications,
electronics, life sciences and chemical analysis. The company's 19,000
employees serve customers in more than 110 countries. Agilent had net
revenue of $5.0 billion in fiscal year 2006. Information about Agilent
is available on the Web at www.agilent.com.
Forward-Looking Statements
This news release contains forward-looking statements as defined
in the Securities Exchange Act of 1934 and is subject to the safe
harbors created therein. The forward-looking statements contained
herein include, but are not limited to, information regarding the
Kalabie product and its enhancement of and integration into our
product portfolio, expectations regarding the contribution Kalabie
would make to Agilent's ability to address customer demands, and the
ability of Agilent to provide improved products, services and support
to its customers as a result of this product acquisition. These
forward-looking statements involve risks and uncertainties that could
cause Agilent's results to differ materially from management's current
expectations. Such risks and uncertainties include, but are not
limited to, risks associated with the integration of the Kalabie
product into Agilent's business model and its product portfolio,
changes in demand for Agilent's products, and risks associated with
the development generally of Agilent's overall strategic objectives.
In addition, other risks that Agilent faces in running its
operations include the ability to execute successfully through
business cycles; ongoing competitive, pricing and gross margin
pressures; the impact of geopolitical uncertainties on our markets and
our ability to conduct business; the ability to improve asset
performance to adapt to changes in demand; the ability to successfully
introduce new products at the right time, price and mix and other
risks detailed in Agilent's filings with the Securities and Exchange
Commission, including its Quarterly Report on Form 10-Q for the period
ended April 30, 2007. Forward-looking statements are based on the
beliefs and assumptions of Agilent's management and on currently
available information. Agilent undertakes no responsibility to
publicly update or revise any forward-looking statement.
NOTE TO EDITORS: Further technology, corporate citizenship and
executive news is available on the Agilent news site at
www.agilent.com/go/news.
CONTACT: Agilent Corporate
Michele Drake, +1-408-345-8396 (Editorial)
michele_drake@agilent.com
or
Agilent LSCA
Stuart Matlow, +1-408-553-7191 (Editorial)
stuart_matlow@agilent.com
or
Agilent
Rodney Gonsalves, +1-408-345-8948 (Investors)
rodney_gonsalves@agilent.com
SOURCE: Agilent Technologies Inc.